Follicular eruptions are well-recognized adverse effects of epidermal growth factor receptor (EGFR) inhibitor therapy.1 Although alopecia is uncommon, mice with targeted disruption of the EGFR develop alopecia.2,3 We report the development of scarring alopecia associated with use of the EGFR inhibitor gefitinib (Iressa; AstraZeneca, Mississisauga, Ontario, Canada).
Donovan JC, Ghazarian DM, Shaw JC. Scarring Alopecia Associated With Use of the Epidermal Growth Factor Receptor Inhibitor Gefitinib. Arch Dermatol. 2008;144(11):1524–1525. doi:10.1001/archderm.144.11.1524
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: